ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

Final Issue Of the Year

December 14, 1990

Study Identifies Risk Factors To Predict Contralateral Cancer

February 27, 2009

Schmidt’s Doubts Threaten Control Saturation Program

August 22, 1975

First “Annual” CCOP RFA Issued; Research Bases Must Compete

June 8, 1990

Federal Science: NASA, NCI Explore Research On Sensor Technologies

August 13, 1999

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010